紫杉醇脂质体单药一线治疗老年晚期非小细胞肺癌的临床观察

doi:10.3971/j.issn.1000-8578.2010.12.024

紫杉醇脂质体单药一线治疗老年晚期非小细胞肺癌的临床观察

Clinical Observation of Paclitaxel Liposome Single-agent on First-line Treatment in Elderly Patients with Advanced Non-small Cell Lung Cancer

摘要

摘要: 目的观察紫杉醇脂质体单药一线治疗老年晚期非小细胞肺癌（NSCLC）的近期疗效及不良反应。方法 21例经病理或细胞学确诊初治老年非小细胞肺癌患者，年龄≥65岁，KPS评分≥70分，其中19例合并程度不等的各种疾病。采用紫杉醇脂质体175mg/m2,静脉给药，每3周给药1次。2周期后评价疗效，观察近期疗效和化疗期间不良反应。结果完全缓解(CR)0例，部分缓解（PR）5例(23.8%)，稳定（SD）10例(47.6%)，进展（PD）6例（28.6%）,有效率RR 23.8%，疾病控制率DCR为71.4%。主要不良反应为血液学毒性、胃肠道反应、肝功能损害,但均以Ⅰ、Ⅱ级为主。发生Ⅲ～Ⅳ级粒细胞减少为3例（14.2％），无感染与发热。无因化疗不良反应导致延迟或终止治疗，无化疗相关性死亡。结论一般状况较好的老年晚期NSCLC患者采用紫杉醇脂质体单药化疗安全、有效，不良反应低，患者耐受性好。

Abstract: Abstract:Objective To observe efficacy and side effects of Paclitaxel liposome single-agent on the first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). Methods Twenty one elderly patients (age≥65 years, KPS≥70) with histologically or cytologically diagnosed advanced NSCLC were treated with Paclitaxel liposome (at a dose of 175mg／m2 day1 as a 3-h infusion on day 1，21days as one cycle)．The therapeutic efficacy was evaluated after 2 cycles of the chemotherapy. Results Among 21 patients all were evaluated for response and toxicity.The overall response rate was 23.8% with complete and partial response rate of 0.0% and 23.8%, respectively; the disease control rate was 71.4%.Adverse events were generally mild, mostly including myelo suppression, gastrointestinal and liver function impairment.There was no treatment-related death. Conclusion The treatment of Paclitaxel liposome showed an effective antitumor activity and a favorable toxicity profile in elderly patientswith NSCLC.

HTML全文

参考文献(0)

施引文献

资源附件(0)